

Patient Access: Early Access, Compassionate Use, Off-label Use

HTA, Pricing,
Reimbursement
and Market Access

TOPICS

- Patient access to orphan drugs and high-price therapies
- Early access schemes in Europe: Are they reimbursed?
- Pricing considerations
- Compassionate use programmes in Europe
- Compounding, off-label use and hospital exemption

YOUR SPEAKERS

Dr Marc Christian Bauer

Agios International GmbH,
Zug, SWITZERLAND

Christian Hill

MAP BioPharma Limited,
Cambridge, GREAT BRITAIN

Dr Alexander Natz, LL.M.

EUCOPE - European Confederation of
Pharmaceutical Entrepreneurs,
Brussels, BELGIUM

Pietro Sternini

Atara Biotherapeutics Switzerland GmbH,
Zug, SWITZERLAND

Patient Access: Early Access, Compassionate Use, Off-label Use

Aims and objectives

This seminar addresses the various options for fast access to innovative medicines in Europe, the reimbursement options and the mechanisms of compounding and off-label use.

Who should attend?

This seminar is intended for workers in the healthcare industry responsible for market access, healthcare management and, in particular, patient access programmes.

Limited number of attendees

This seminar is limited to 20 participants. This limitation, a feature of all FORUM seminars, enables participants to thoroughly discuss the complex issues covered by the programme.

Your benefits

- Detailed knowledge of the various patient access options in Europe
- The latest on compassionate use in Europe
- Patient access options and HTA reality check, all in one seminar

YOUR SPEAKERS



Dr Marc Christian Bauer

Agios International GmbH, Zug, SWITZERLAND

Vice President, Head of Legal and Compliance International/GM DACH



Christian Hill

MAP BioPharma Limited, Cambridge, GREAT BRITAIN

Chief Executive Officer



Dr Alexander Natz, LL.M.

EUCOPE, Brussels, BELGIUM

Secretary General



Pietro Sternini

Atara Biotherapeutics Switzerland GmbH, Zug, SWITZERLAND

Head of Market Access Europe

Your programme from 09:00 - 17:00

09:00

Patient access to orphan drugs and other high-price therapies - status throughout Europe

Christian Hill

09:45

Early access schemes and the HTA reality

Christian Hill

- What is the legal basis in the EU?
- How does the practice differ from one EU country to the other?
- Reimbursed early access or free of charge supply?
- Who takes legal responsibility: the company or the physician?
- What can we learn from case studies?

11:15 Coffee break

11:30

Pricing considerations for early access models for high-price drugs

Dr Alexander Natz

- Pay for performance revival?
- Payer contracting prior to HTA assessment?
- How to use the data generated

13:00 Lunch

14:30

Compassionate use programmes (CUPs) in Europe

Dr Marc Christian Bauer

- The role of patient organisations and payers
- How to enable patient access between FDA and EU approval
- Some case studies on how to set up CUPs in the EU

15:45 Coffee break

16:00

Compounding, off-label use and the hospital exemption for cell therapies (ATMPs)

Pietro Sternini

- ATMPs made by hospitals and the hospital exemption
- Compounding pharmacies
- Off-label use

17:00 Seminar end

Patient Access: Early Access, Compassionate Use, Off-label Use

REGISTRATION UNDER

service@forum-institut.com
www.forum-institut.com
Webcode 2006235

Tel. +49 6221 500-500
Fax +49 6221 500-555



REGISTRATION FORM

Yes, I will attend

☐ Patient Access: Early Access, Compassionate Use, Off-label Use

☐ Yes, I agree that FORUM Institut may inform me about events by:
☐ email; and/or ☐ telephone.
I may withdraw my consent at any time.

Date and venue

Tuesday, 30 June 2020 in Frankfurt

08:30 registration
09:00 - 17:00 uhr seminar

Mercure Hotel Kaiserhof Frankfurt City Center
Kaiserstraße 62-64
60329 Frankfurt
Tel. 069 256 1790

Name

Position, department

Company

Street

Post code, city, country

Tel. no./Fax no.

E-mail

Contact person at office

Date, signature

Fee

€ 1190.00 (+ German VAT)

The fee includes course documentation (including free download) as well as refreshments, lunch and a certificate. You will receive an invoice as well as confirmation.

CANCELLATION POLICY

Our general terms and conditions (as of 1 January 2016) apply and are available upon request. We can send them to you at any time. Alternatively, you can access them online at www.forum-institut.com/t&c

YOUR CONTACT



Dr. Henriette Wolf-Klein
Head of Department
Tel. +49 6221 500-680
h.wolf-klein@forum-institut.de

